Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Nephrology
Published in: Journal of Nephrology 5/2022

21-05-2022 | Erythropoietin | Case Report

Cyclic thrombocytopenia related to erythropoietin-dependent anti-platelet anti-GPIV/IIIb antibody in hemodialysis

Authors: Nans Florens, Jean-Claude Bordet, Catherine Giannoli, Emilie Le Toriellec, Fitsum Guebre-Egziabher

Published in: Journal of Nephrology | Issue 5/2022

Login to get access

Abstract

We describe herein the case of a 65-year-old patient on chronic hemodialysis with a medical history of idiopathic thrombocytopenia who experienced numerous episodes of severe thrombocytopenia with no specific diagnosis. Further analysis of the evolution of the platelet count showed that cyclic thrombocytopenia occurred after each injection of recombinant erythropoietin (rHu-EPO). Exploration of the involved mechanisms revealed the presence of a rHu-EPO-dependent anti-GPIV/IIIb antibody associated with a significant increase in GPIV/IIIb expression on her platelets after the addition of rHu-EPO. EPO was discontinued and the patient was treated with roxadustat with favorable results on her hemoglobin and platelet counts.
Appendix
Available only for authorised users
Literature
1.
Chateauvieux S, Grigorakaki C, Morceau F, Dicato M, Diederich M (2011) Erythropoietin, erythropoiesis and beyond. Biochem Pharmacol 82:1291–1303CrossRef
2.
Casadevall N et al (1996) Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med 334:630–633CrossRef
3.
Casadevall N et al (2002) Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469–475CrossRef
4.
Beguin Y (1999) Erythropoietin and platelet production. Haematologica 84:541–547PubMed
5.
Stohlawetz PJ et al (2000) Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 95:2983–2989CrossRef
6.
Eschbach JW et al (1989) Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 111:992–1000CrossRef
7.
McDonald TP, Clift RE, Cottrell MB (1992) Large, chronic doses of erythropoietin cause thrombocytopenia in mice. Blood 80:352–358CrossRef
8.
Shin SK et al (2011) Anti-erythropoietin and anti-thrombopoietin antibodies induced after administration of recombinant human erythropoietin. Int Immunopharmacol 11:2237–2241CrossRef
9.
Aster RH, Bougie DW (2007) Drug-induced immune thrombocytopenia. N Engl J Med 357:580–587CrossRef
10.
Smith KJ, Bleyer AJ, Little WC, Sane DC (2003) The cardiovascular effects of erythropoietin. Cardiovasc Res 59:538–548CrossRef
11.
Demetz G et al (2014) The influence of Erythropoietin on platelet activation, thrombin generation and FVII/active FVII in patients with AMI. Thromb J 12:18CrossRef
12.
Gambardella L et al (2016) Gender difference in platelet aggregation and reactivity induced by recombinant human erythropoietin. Br J Clin Pharmacol 81:789–791CrossRef
13.
Gupta N, Wish JB (2017) Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD. Am J Kidney Dis 69:815–826CrossRef
14.
Egrie JC, Browne JK (2001) Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 84:3–10CrossRef
Metadata
Title
Cyclic thrombocytopenia related to erythropoietin-dependent anti-platelet anti-GPIV/IIIb antibody in hemodialysis
Authors
Nans Florens
Jean-Claude Bordet
Catherine Giannoli
Emilie Le Toriellec
Fitsum Guebre-Egziabher
Publication date
21-05-2022
Publisher
Springer International Publishing
Published in
Journal of Nephrology / Issue 5/2022
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-022-01348-3

Other articles of this Issue 5/2022

Journal of Nephrology 5/2022 Go to the issue

original Article

Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients

original Article

Patient perspectives on chronic kidney disease and decision-making about treatment. Discourse of participants in the French CKD-REIN cohort study

Commentary

Referral of patients with chronic kidney disease: inconsistencies between guidelines and real-life practice, more questions than answers

original Article

Dialysis symptom index burden and symptom clusters in a prospective cohort of dialysis patients

original Article

Early morning hemodynamic changes and left ventricular hypertrophy and mortality in hemodialysis patients

original Article

Intradialytic hypotension and objectively measured physical activity among patients on hemodialysis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits